» Articles » PMID: 1637135

The Spectrum of Neurological Disease in Patients with Systemic Cancer

Overview
Journal Ann Neurol
Specialty Neurology
Date 1992 Mar 1
PMID 1637135
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

To ascertain the range of neurological problems in patients with systemic cancer, we prospectively evaluated neurological symptoms, neurological diagnoses, and primary tumors in all patients with a history of systemic cancer examined by the Department of Neurology at the Memorial Sloan-Kettering Cancer Center, from Jul 1, 1990, to Dec 31, 1990. Of the 815 patients seen for neurological symptoms, less than half (45.2%) had metastatic involvement of the nervous system. The three most common symptoms were back pain (18.2%), altered mental status (17.1%), and headache (15.4%). The most common neurological diagnosis was brain metastasis (15.9%), followed by metabolic encephalopathy (10.2%), pain associated with bone metastases only (9.9%), and epidural extension or metastasis of tumor (8.4%). Of 133 patients with undiagnosed back or neck pain, 44 (33%) had epidural extension or metastases from tumor and 40 (30%) had pain associated with vertebral metastases only. In 15 (11%) the cause for the back pain was unrelated to metastatic disease. Of 132 patients seen on initial consultation for altered mental status, metabolic encephalopathy was the major neurological diagnosis (80; 61%); 20 (15%) had intracranial metastases. Of 97 patients with undiagnosed headache, 59 (61%) had a nonstructural cause. Fifty-three of these patients had either migraine, tension headache, or headache related to systemic illness (e.g., fever, sepsis). These results indicate that even in patients with systemic cancer, a group particularly prone to developing neurological disease that can be diagnosed radiologically, the role of clinicians remains important in helping distinguish noncancer-related and nonmetastatic neurological problems.

Citing Articles

Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.

Vaiana A, Chen Y, Gelfond J, Johnson-Pais T, Leach R, Ramamurthy C Transl Psychiatry. 2023; 13(1):307.

PMID: 37788996 PMC: 10547695. DOI: 10.1038/s41398-023-02600-5.


Presence of Activated (Phosphorylated) STAT3 in Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases.

Jablonska P, Galan N, Barranco J, Leon S, Robledano R, Echeveste J Int J Mol Sci. 2023; 24(18).

PMID: 37762522 PMC: 10532304. DOI: 10.3390/ijms241814219.


Remote assessment of cognition and quality of life following radiotherapy for glioma: deep-learning-based predictive models and MRI correlates.

Voon N, Manan H, Yahya N J Neurooncol. 2023; 162(2):407-415.

PMID: 37014593 PMC: 10071464. DOI: 10.1007/s11060-023-04303-9.


Role of miR‑200 family in brain metastases: A systematic review.

Fotakopoulos G, Georgakopoulou V, Spandidos D, Papalexis P, Angelopoulou E, Aravantinou-Fatorou A Mol Clin Oncol. 2023; 18(3):15.

PMID: 36798467 PMC: 9926042. DOI: 10.3892/mco.2023.2611.


Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis.

Hahn J, Jo Y, Yoo S, Shin J, Yu Y, Ah Y Front Pharmacol. 2022; 13:1009950.

PMID: 36304170 PMC: 9593000. DOI: 10.3389/fphar.2022.1009950.